Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis

Neurology

Volumn 53, Issue 4, 1999, Pages 758-764

  Khoury, S J ^a,c   Orav, E J ^b   Guttmann, C R G ^a   Kikinis, R ^a   Jolesz, F A ^a   Weiner, H L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Center for Neurologic Diseases   (United States)

Author keywords

Brain MRI; MS; Soluble intercellular adhesion molecule 1; Soluble tumor necrosis factor receptors

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE;

EID: 0033546947     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.4.758     Document Type: Article

References (42)

1. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409-421.
2. Adams CW, Poston RN, Buk SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989;92:291-306.
3. Gay D, Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 1991; 114(pt 1B):557-572.
4. Khoury SJ, Weiner HL. Multiple sclerosis: what have we learned from magnetic resonance imaging studies? Arch Intern Med 1998;158:565-573.
5. Paty D, Li D, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667.
6. Jacobs LD, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Multiple Sclerosis 1995;1:118-135.
7. Weiner HL, Khoury SJ, Guttman C, et al. Magnetic resonance imaging correlates with clinical disability and attacks in multiple sclerosis. Neurology 1998;50:A322-A323.
8. Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-512.
9. Sobel RA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol 1990;136:1309-1316.
10. Sharief M, Noori M, Ciardi M, et al. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-α and blood-brain barrier damage. J Neuroimmunol 1993;43:15-22.
11. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N. Increased levels of circulating adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type-1 associated myelopathy. Ann Neurol 1993;33:646-649.
12. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997;41:326-333.
13. Giovannoni G, Lai M, Thorpe J, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997;48:1557-1565.
14. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of Lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954.
15. Cannella B, Riane CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
16. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestations in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
17. Sharief MK, Henteges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
18. Chofflon M, Julliard C, Julliard P, Gauthier G, Grau GE. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992;3:523-531.
19. Riekmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
20. Heller RA, Kronke M. Tumor necrosis factor receptor-mediated signaling pathways. J Cell Biol 1994;126:5-9.
21. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-962.
22. Riekmann P, Martin S. Weichselbraun I, et al. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 1994;44:2367-2372.
23. Spuler S, Yousry T, Scheller A, et al. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. J Neuroimmunol 1996;66:57-64.
24. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46:907-911.
25. Kikinis R, Guttmann CRG, Metcalf D, et al. Quantitative follow-up of patients with multiple sclerosis using MRI: technical aspects. J Magn Reson Imaging 1999;9:519-530.
26. Guttmann CRG, Kikinis R, Anderson MC, et al. Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility. J Magn Reson Imaging 1999;9:509-518.
27. Wells WM, Grimson WEL, Kikinis R, Jolesz FA. Adaptive segmentation of MRI data. IEEE Trans Med Imaging 1996;15: 429-442.
28. Metcalf D, Kikinis R, Guttmann CRG, Vaina L, Jolesz F. 4D connected component labelling applied to quantitative analysis of MS lesion temporal development. In: Proceedings of the 14th annual international conference of the IEEE-EMBS; Paris, 1992;3:945-946.
29. Liang K-Y, Zeger SI. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
30. Khoury S, Guttmann C, Orav E, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124.
31. Martino G, Consiglio A, Franciotta DM, et al. Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis. J Neurol Sci 1997;152:51-61.
32. Leeuwenberg JF, Jeunhomme TM, Buurman WA. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 1994;152:4036-4043.
33. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992;175:323-329.
34. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534.
35. Trojano M, Avolio C, Rugieri M, et al. Soluble intercellular adhesion molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. Multiple Sclerosis 1998;4:39-44.
36. Franciotta D, Piccolo G, Zardini E, Bergamaschi R, Cosi V. Soluble CDS and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. Acta Neurol Scand 1997; 95:275-279.
37. Droogan AG, McMillan SA, Douglas JP, Hawkins SA. Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular call adhesion molecule-1. J Neuroimmunol 1996;64:185-191.
38. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599-603.
39. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlated with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102:671-678.
40. Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition of T cell responses by activated human CDS+ T cells is mediated by Interferon-γ and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995;95:2711-2719.
41. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N. Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1 associated myelopathy. J Neuroimmunol 1995;59:35-40.
42. Trotter S, Clifford D, Anderson C. Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis. N Engl J Med 1988;319:1019-1020.